ReviewCancer letters2014
Delineating an epigenetic continuum in head and neck cancer.
Review in Cancer letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Methylation related genes are associated with prognosis of patients with head and neck squamous cell carcinoma via altering tumor immune microenvironment.Journal of dental sciences · 2023Article
- High eukaryotic initiation factor 5A2 expression predicts poor prognosis and may participate in the SNHG16/miR-10b-5p/EIF5A2 regulatory axis in head and neck squamous cell carcinoma.Journal of clinical laboratory analysis · 2023Article
- Prognostic and therapeutic prediction by screening signature combinations from transcriptome-methylome interactions in oral squamous cell carcinoma.Scientific reports · 2022Article
- Epithelial-to-Mesenchymal Transition-Derived Heterogeneity in Head and Neck Squamous Cell Carcinomas.Cancers · 2021Review
- Review
- Methylation-Driven Genes Identified as Novel Prognostic Indicators for Thyroid Carcinoma.Frontiers in genetics · 2020Article
- DNA methylation-mediated Klotho silencing is an independent prognostic biomarker of head and neck squamous carcinoma.Cancer management and research · 2019Article
- Article
- DNA methylation biomarkers for head and neck squamous cell carcinoma.Epigenetics · 2018Article
- Deciphering the Role of the Barr Body in Malignancy: An insight into head and neck cancer.Sultan Qaboos University medical journal · 2017Review
- Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.International journal of molecular sciences · 2017Review
- WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers.BMC cancer · 2016Article
- NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.BMC cancer · 2015Article
- Epigenetic changes in the CDKN2A locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma.Cancer medicine · 2015Article
- Genome-Wide Scan for Methylation Profiles in Keloids.Disease markers · 2015Article
- HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas.The Journal of clinical investigation · 2013Article
- Molecular characterization of head and neck cancer: how close to personalized targeted therapy?Molecular diagnosis & therapy · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A tissue field of somatic genetic alterations precedes the histopathological phenotypic changes of carcinoma. Genomic changes could be of potential use in the diagnosis and prognosis of pre-invasive squamous head and neck carcinoma (HNSCC) lesions and as markers for cancer risk assessment. Studies of sequential molecular alterations and genetic progression of pre-invasive HNSCC have not been clearly defined. Studies have shown recurring alterations at chromosome 9p21 (location of the CDKN2A) and TP53 mutations in the early stages of HNSCC. However, gene silencing via hypermethylation is still a relatively new idea in the development of HNSCC and little is known about the contribution of epigenetics to the development of neoplasia, its transformation, progression, and recurrence in HNSCC. This review examines the role of promoter hypermethylation of tumor suppressor genes in the progression continuum from benign papillomas to malignancy in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.